Cytotrait Ltd.

Cover Block

Field	Value
Name	Cytotrait Ltd.
Tagline	Biotechnology company providing plant organelle gene-editing technology
Headquarters	Manchester, UK
Founded	2023
Stage	Pre-Seed / Seed
Business Model	B2B
Industry	Agtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Dr. Junwei Ji (Co-Founder, Executive Director)
Funding Label	£3M Seed
Total Disclosed	~$4.03M

Links

• Website: https://www.cytotrait.com

Executive Summary

Cytotrait Ltd. is a University of Manchester biotechnology spinout developing organelle gene-editing tools for crops [University of Manchester]. The company was founded in 2023 by Dr. Junwei Ji and in March 2026 closed a £3M (approximately $4.03M) seed round led by Northern Gritstone, with participation from the UK Innovation & Science Seed Fund [AgTechNavigator, March 2026]; [Tech.eu, March 2026]. Its core asset is the MOSS platform (Mutant Organelle Selection System), which enables ultra-high trait expression by removing unedited copies of the chloroplast or mitochondrial genome so that edited copies propagate to homoplasmy [AgTechNavigator, March 2026]; [Tech Funding News]. The team has reported demonstrating the approach in two crops and is targeting wheat, maize, potato, and canola as initial commercial substrates [iGrow News, 2026]; [The Bae HQ, March 2026]. Northern Gritstone also runs the NG Studios spinout program through which Cytotrait was incubated [Prolific North]. The business model is B2B, oriented toward licensing engineered traits or partnering with seed and trait developers. Over the next 12 to 18 months, the most informative signals will be peer-reviewed validation of the MOSS mechanism, the first announced trait partnership with a major seed company, and progress through UK and EU gene-editing regulatory frameworks.

Data Accuracy: GREEN -- Confirmed by AgTechNavigator (March 2026), University of Manchester, Tech.eu (March 2026), and Northern Gritstone press coverage in Prolific North.

Taxonomy Snapshot

Axis	Value
Stage	Seed (£3M closed March 2026)
Business Model	B2B (trait licensing / partnership)
Industry / Vertical	Agtech, plant biotechnology
Technology Type	Organelle gene editing (chloroplast, mitochondrial)
Geography	Manchester, UK (Western Europe)
Growth Profile	Venture Scale, deep-tech
Founding Team	University of Manchester academic spinout
Funding	£3M / ~$4.03M disclosed

How the Company Got Here

Cytotrait was incorporated in 2023 as a spinout from the University of Manchester, where the underlying organelle-editing research originated in Dr. Junwei Ji's laboratory [University of Manchester]; [Preqin]. The commercial vehicle was assembled with support from the University of Manchester Innovation Factory and NG Studios, the venture studio operated by Northern Gritstone [University of Manchester Innovation Factory]; [Prolific North]. The legal entity is registered in England as Cytotrait Ltd. [Cytotrait].

The company spent its first roughly two years pre-seed before closing its institutional seed round in early 2026 [University of Manchester Innovation Factory]; [Business Live]. The £3M seed was announced on 9 March 2026, with Northern Gritstone leading and the UK Innovation & Science Seed Fund participating [Tech.eu, March 2026]; [Startupmag]. Coverage at the time of the round emphasised that the MOSS platform had been demonstrated in two crops [AgTechNavigator, March 2026].

Manchester hosts one of the larger UK plant science groupings, and Northern Gritstone is structurally tied to commercialising research from the northern English university triangle. Cytotrait sits in a growing cohort of UK plant-biotech spinouts that have raised institutional seed capital since the 2023 passage of the Genetic Technology (Precision Breeding) Act [The Bae HQ, March 2026].

Data Accuracy: GREEN -- Confirmed by University of Manchester, Cytotrait company terms, AgTechNavigator (March 2026), and Prolific North.

Product and Technology

Cytotrait's product is a platform rather than a finished trait. The MOSS (Mutant Organelle Selection System) platform addresses a technical bottleneck in organelle engineering: plant cells contain many copies of the chloroplast and mitochondrial genomes per cell, and edits typically reach only a fraction of those copies, producing heteroplasmic plants [AgTechNavigator, March 2026]; [Tech Funding News]. MOSS works by selectively removing the unedited genome copies so that edited copies can propagate to homoplasmy [AgTechNavigator, March 2026]. The company has stated the approach has been demonstrated in two crops [AgTechNavigator, March 2026].

The stated commercial targets are staple field crops: wheat, maize, potato, and canola [iGrow News, 2026]; [The Bae HQ, March 2026]. Chloroplast engineering at scale in monocots such as wheat and maize has been a long-standing unsolved problem in plant biotechnology. The choice of substrates suggests Cytotrait is positioning MOSS as a horizontal enabler across both monocot and dicot row crops. Reported applications include yield, stress tolerance, and trait stacking [University of Manchester]; [International Biopharmaceutical Industry].

Data Accuracy: YELLOW -- Mechanism described consistently across AgTechNavigator, Tech Funding News, iGrow News and The Bae HQ, but no peer-reviewed publication or patent filing has been independently confirmed in the captured sources.

Market Research and Opportunity

Demand drivers include climate stress on cereal yields, geopolitical pressure on fertilizer supply, and the unwinding of older glyphosate-tolerance trait packages. Major incumbents (Bayer, Corteva, BASF, Syngenta) have publicly recommitted to gene-edited trait pipelines.

The regulatory tailwind is the most concrete near-term driver. The UK's Genetic Technology (Precision Breeding) Act, which received Royal Assent in 2023, creates a distinct and lighter regulatory class in England for plants produced by precision breeding techniques. The European Union has been advancing a parallel proposal to create a category of New Genomic Techniques plants subject to lighter oversight than the existing GMO regime.

Key adjacent and substitute markets include nuclear-genome CRISPR trait platforms, conventional and marker-assisted breeding, and biological inputs. Organelle editing is differentiated because chloroplasts can carry very high copy numbers of an engineered gene per cell, and because maternal inheritance of plastid genomes in many crops constrains pollen-mediated gene flow.

Metric	Value
Cytotrait seed round, March 2026	£3M / ~$4.03M
Stated initial crop targets	Wheat, maize, potato, canola
Crops with reported MOSS demonstration	2

Data Accuracy: YELLOW -- Round size and crop targets confirmed across multiple outlets; market sizing relies on category context rather than a named third-party report for the organelle-editing sub-segment specifically.

Competitive Landscape

The nearest segment is nuclear-genome CRISPR trait development for row crops, where the most visible private platforms are Inari Agriculture, Pairwise, and Tropic Biosciences. A second adjacent segment is the chloroplast-engineering academic and small-company space. A third segment is the incumbent seed and trait majors (Bayer, Corteva, Syngenta, BASF) who are realistic future licensees or acquirers.

Cytotrait can plausibly hold a defensible edge if MOSS genuinely delivers reliable homoplasmy in monocots, a capability the broader chloroplast engineering field has been pursuing for two decades. That edge is exposed on two fronts. First, the much larger nuclear-CRISPR platforms can address many of the same end traits without needing to solve the organelle problem. Second, distribution into the seed channel is controlled by a very small number of multinationals; without a partnership announcement, the path from platform to commercial trait runs through gatekeepers Cytotrait does not yet own.

Data Accuracy: ORANGE -- Cytotrait facts confirmed; competitor set inferred from category knowledge rather than named in captured sources.

Opportunity

If MOSS works as described across multiple crops, Cytotrait is positioned to become the default organelle-editing layer for the global seed industry.

The headline opportunity. The single largest outcome is platform status: MOSS becomes the licensed enabling technology that any seed company or trait developer uses when they want to engineer chloroplast or mitochondrial traits. The underlying technical problem (heteroplasmy in edited organelle genomes) is well-defined and has resisted clean commercial solution for years [AgTechNavigator, March 2026]; [Tech Funding News].

Growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Platform licensor	Cytotrait signs non-exclusive evaluation deals with two of Bayer / Corteva / Syngenta / BASF	First peer-reviewed MOSS demonstration in wheat or maize	UK Precision Breeding Act and pending EU NGT framework [The Bae HQ, March 2026]
Vertical trait developer	Cytotrait develops one or two flagship traits for direct licensing	Demonstrated yield or input-reduction data in field trials	Northern Gritstone's regional commitment [Prolific North]
Acquisition	Strategic buyer absorbs the platform after Series A validation	Independent replication of MOSS in a third crop	Seed majors have a documented pattern of acquiring platform-stage gene-editing companies

Data Accuracy: YELLOW -- Scenarios are framed against confirmed Cytotrait facts and category comparables; specific valuation translations are explicitly labelled as scenarios rather than forecasts.

Sources

1. [Preqin] Cytotrait Ltd. Asset Profile | https://www.preqin.com/data/profile/asset/cytotrait-ltd-/792424
2. [Cytotrait] Terms of Use and Privacy Policy | https://www.cytotrait.com/terms-of-use-and-privacy-policy
3. [AgTechNavigator, March 2026] Cytotrait claims breakthrough for ultra-high trait expression as it closes £3M seed round | https://www.agtechnavigator.com/Article/2026/03/10/cytotrait-claims-breakthrough-for-ultrahigh-trait-expression-as-it-closes-3m-seed-round/
4. [University of Manchester] Biotechnology spinout Cytotrait secures £3M seed funding to address global food security and sustainable agriculture | https://www.manchester.ac.uk/about/news/biotechnology-spinout-cytotrait-secures-seed-funding/
5. [Tech Funding News] Cytotrait bags £3M to bring organelle engineering to wheat, maize and potato farms | https://techfundingnews.com/manchester-spinout-cytotrait-bags-3m-to-build-more-resilient-crops/
6. [iGrow News, 2026] Cytotrait Secures $4M to Advance MOSS Crop Technology | https://igrownews.com/cytotrait-latest-news/
7. [Pulse 2.0] Cytotrait: £3 Million Seed Funding Raised For Crop Engineering Technology | https://pulse2.com/cytotrait-3-million-seed-funding-raised-for-crop-engineering-technology/
8. [International Biopharmaceutical Industry] Cytotrait secures £3M seed funding to address global food security and sustainable agriculture | https://international-biopharma.com/cytotrait-secures-3m-seed-funding-to-address-global-food-security-and-sustainable-agriculture/
9. [Prolific North] Northern Gritstone leads £3m seed fund for Manchester Uni biotech spinout | https://www.prolificnorth.co.uk/news/northern-gritstone-leads-3m-seedfund-for-manchester-uni-biotech-spinout/
10. [The Bae HQ, March 2026] Cytotrait Raises £3M to Apply Its Organelle-Targeting MOSS Platform to Wheat, Maize, Potato and Canola | https://www.thebaehq.com/news/cytotrait-raises-3m-northern-gritstone-crop-engineering-moss
11. [Tech.eu, March 2026] Cytotrait raises £3M for agricultural gene-editing technology | https://tech.eu/2026/03/09/cytotrait-raises-ps3m-for-agricultural-gene-editing-technology/
12. [University of Manchester Innovation Factory] Cytotrait secures £3M seed funding to address global food security and sustainable agriculture | https://www.uominnovationfactory.com/news/cytotrait/
13. [Business Live] £3m seed funding for crop biotech firm Cytotrait | https://www.business-live.co.uk/technology/3m-seed-funding-crop-biotech-33559827
14. [Startupmag] Cytotrait secures £3m seed to boost yields via chloroplast and mitochondrial edits | https://www.startupmag.co.uk/funding/cytotrait-2026-seed-funding/